We focus on therapies for the treatment of bronchopulmonary disease
This section of the website provides information for existing and potential investors in Vectura Group plc including financial reports, an interactive share price chart and updates on our latest news.
Vectura's focused application of technology, know-how and expertise has demonstrated that the potential for new inhaled pharmaceuticals with real therapeutic and commercial value can be realised.
JP Morgan Healthcare Conference, San Francisco, California
Vectura Group plc interim results for the six months ending 30 September 2013
Annual Report and Accounts for Year Ended 31 March 2013
28 Feb 2014
South Korean Regulatory Authority confirm approval of AirFluSal® Forspiro®
12 Feb 2014
Belgian Regulatory Authority confirm approval of AirFluSal® Forspiro®
03 Mar 2014
Total Voting Rights
28 Feb 2014
South Korean approval of AirFluSal Forspiro
Share price table
Investor Day, London
Final Results for the year ending 31 March 2014
Stay informed Register to our news alert and receive latest updates on news and events
For general enquiries, call us on +44 (0)1249 667700. For more specific enquiries, visit Contact us
Most computers will open PDF documents automatically, but you may need to download Adobe Reader.